Nootropic drugs in patients with non-dementia vascular cognitive impairment
M. N. Dadasheva, R. V. Gorenkov, V. A. Kruglov, K. N. Dadasheva, D. I. Lebedeva · 2022 · Neurology, Neuropsychiatry, Psychosomatics. 2022;14(2):49–55.
Study data at a glance
- Participants or experimental model
- 150 patients randomized into three groups of 50: omberacetam, piracetam/cinnarizine or aminophenylbutyric acid, alongside baseline care; 45 days.
- Reported results
- The abstract reports a MoCA increase from 19.8 to 23.3 in the omberacetam group at day 45. At the later assessment, the score remained 0.8 points above baseline (p=0.061), which does not establish a persistent statistically significant effect.
Molekul summary of the linked publication. Educational information, not medical advice. Seek qualified healthcare help for medical conditions.
Methods, limitations & source review
Study limitations
- Randomization is stated in the abstract, but allocation concealment and blinding are not established by this review. Active comparators, without a described placebo arm.
- The abstract inconsistently describes follow-up as 3.5 and 4.5 months and prints an unusual inequality for some p-values; these require original-text reconciliation.
- A within-group score increase does not by itself establish superiority over the other treatments.
Publication counts are not counts of independent trials. Reviews, translations and reports sharing participants may overlap. Findings apply to the studied preparation, population and endpoints.
Review depth: Primary-publication abstract and metadata; complete methods not appraised
Source access and review scope
Russian primary-publication abstract reproduced by RusMed checked; complete trial methods and numerical between-group comparisons not appraised.
Recorded source-check date: 2026-11-01. This date does not imply a completed systematic review.
Source type: Journal publication
Citation and original source
Original source: M. N. Dadasheva, R. V. Gorenkov, V. A. Kruglov, K. N. Dadasheva, D. I. Lebedeva. Nootropic drugs in patients with non-dementia vascular cognitive impairment Neurology, Neuropsychiatry, Psychosomatics. 2022;14(2):49–55. 2022.
Molekul research summary: https://molekul.io/research/noopept-vascular-comparison-2022. Cite the original publication for its findings and this page when referring to Molekul’s summary or evidence appraisal.
Bibliography entry